PuraCap Makes Acquisition to Expand Solid Dosage ManufacturingBy
Puracap Pharmaceutical LLC, based in South Plainfield, New Jersey, has acquired Blu Pharmaceutical LLC and Blu Caribe Inc to create PuraCap International LLC, a joint venture between PuraCap and Dangdai International Group Co., Ltd. This acquisition will expand PuraCap's manufacturing expertise beyond soft gelatin capsules to include oral tablet and capsule dosage forms for the both the US and global markets.
The acquisition increases Puracap’s capabilities for manufacturing oral solid dosage forms in the United States, which complements its soft-gelatin capsule manufacturing facility in Wuhan, China. The acquisition includes a 145,000-square foot. FDA approved, cGMP compliant manufacturing facility in Dorado, Puerto Rico, as well as an 185,000-square-foot warehouse and distribution center in Franklin, Kentucky.
PuaCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing,and distribution. PuraCap's corporate structure supports a two-pronged approach for global growth in the areas of prescription brands (PuraCap Pharmaceutical LLC) as well as prescription generics and over-the-counter and private label brands (PuraCap International LLC).
Founded in 1988, Wuhan Dangdai Science & Technology Industries (Group) Co., Ltd is a China-based privately held conglomerate. Its portfolio is comprised of several Chinese publicly listed entities and private companies in North America and Africa. Wuhan Dangdai's enterprise includes biopharmaceuticals, media, entertainment, real estate development, tourism, agriculture, textile and financial services.
source: Puracap Pharmaceutical